ArticleBioinformation2025
Characterization of clear cell - Renal cell carcinoma using neutrophil - Lymphocyte ratio.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The features of tumour in clear cell - renal cell carcinoma are evaluated using neutrophil - lymphocyte ratio for its prognosis. Hence, 186 clear cell-renal cell carcinoma patients with documented neutrophil lymphocyte ratio were obtained. Depending on the features of the lesion, patients underwent either a partial or radical nephrectomy and characteristics were studied in relation to normal or high neutrophil - lymphocyte ratio with a cut-off of 2.7. Of the 186 patients studied, 131 had a normal neutrophil lymphocyte ratio (<2.7), while 55 presented with an elevated neutrophil lymphocyte ratio (≥2.7). Elevated neutrophil lymphocyte ratio was significantly associated with both tumor size and renal vein invasion, with a p-value of less than 0.001. Thus, the neutrophil lymphocyte ratio is a valuable metric for assessing renal vein extension and predicting tumour size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.